[Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
OBJECTIVE
To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.


METHODS
Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control. The possible correlation of hMAM mRNA expression with clinico-pathological parameters and related molecular markers such as Ki67, p53 and VEGF were analyzed.


RESULTS
The sensitivity of RT-PCR in this series reached 10(-6). The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%. However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers. The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).


CONCLUSIONS
RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients. Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients. Positive hMAM mRNA expression result may have an impact upon therapeutic recommendations and patients' prognostic judgement.
Li
Bao-Jiang
BJ
Oncosurgery of Taian central hospital, Taian 271000, China.
Wang
Jun-Ye
JY
Wang
Hong-Yue
HY
Huang
Xiao-Ping
XP
Zhang
Lan-Jun
LJ
Long
Hao
H
Yang
Ming-Tian
MT
Rong
Tie-Hua
TH
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000235:genetics; D001853:Bone Marrow / Q000378:metabolism* / Q000473:pathology; D001940:Breast / Q000378:metabolism / Q000473:pathology; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology; D018567:Breast Neoplasms, Male / Q000235:genetics* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics / Q000473:pathology; D005260:Female; D018226:Fibroadenoma / Q000235:genetics / Q000473:pathology; D006801:Humans; D019394:Ki-67 Antigen / Q000235:genetics; D008207:Lymphatic Metastasis; D008297:Male; D060785:Mammaglobin A; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000235:genetics*; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D011980:Receptors, Progesterone / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014598:Uteroglobin / Q000235:genetics*
D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D060785:Mammaglobin A; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D011980:Receptors, Progesterone; C556448:SCGB2A2 protein, human; D014598:Uteroglobin